Exelixis (EXEL) Total Current Liabilities (2010 - 2026)
Exelixis (EXEL) posted quarterly Total Current Liabilities of $371.0 million for Q2 2026, down 7.05% year-over-year from $399.1 million in Q2 2025, and down 8.55% quarter-over-quarter from $405.6 million in Q1 2026.
Analysis
Exelixis (EXEL) Total Current Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $371.0 million for Q2 2026.
- In Q2 2026, Total Current Liabilities fell 7.05% year-over-year to $371.0 million; the TTM figure through Apr 2026 stood at $371.0 million (down 7.05% YoY), while the FY2026 annual figure was $405.6 million, changed 0.46% from the prior year.
- Total Current Liabilities for Q2 2026 stood at $371.0 million, down from $405.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $405.6 million in Q1 2026, with the low at $289.1 million in Q2 2022.
- The 5-year median for Total Current Liabilities is $371.0 million (2026), against an average of $356.5 million.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities jumped 35.5% in 2022, then slipped 7.05% in 2026.
- Exelixis' Total Current Liabilities stood at $324.4 million in 2022, then gained by 21.56% to $394.3 million in 2023, then advanced by 0.02% to $394.3 million in 2024, then dropped by 5.22% to $373.8 million in 2025, then declined by 0.75% to $371.0 million in 2026.
- Business Quant data shows EXEL's Total Current Liabilities at $371.0 million in Q2 2026, $405.6 million in Q1 2026, and $373.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 361.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 361.93 Mn |
| Apr 3, 2026 | 370.98 Mn |
| Jan 2, 2026 | 405.64 Mn |
| Oct 3, 2025 | 373.78 Mn |
| Jul 4, 2025 | 336.11 Mn |
| Apr 4, 2025 | 399.10 Mn |
| Jan 3, 2025 | 403.77 Mn |
| Sep 27, 2024 | 394.35 Mn |
| Jun 28, 2024 | 345.70 Mn |
| Mar 29, 2024 | 373.01 Mn |
| Dec 29, 2023 | 394.28 Mn |
| Sep 29, 2023 | 376.82 Mn |
| Jun 30, 2023 | 339.62 Mn |
| Mar 31, 2023 | 327.60 Mn |
| Dec 30, 2022 | 324.36 Mn |
| Sep 30, 2022 | 301.73 Mn |
| Jul 1, 2022 | 304.52 Mn |
| Apr 1, 2022 | 289.08 Mn |
| Dec 31, 2021 | 337.59 Mn |
| Oct 1, 2021 | 269.51 Mn |